Quiz: Why is BXLT’s gene-therapy candidate for hemophilia A about two years behind its gene-therapy candidate for hemophilia B? (Hint: This is not a business decision; the hemophilia-A market is ~4x larger than the hemophilia-B market.)
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”